ImaginAb

Imagin Ab

Biotechnology, 423 Hindry Ave Ste D, Inglewood, California, 90301, United States, 11-50 Employees

imaginab.com

  • twitter
  • LinkedIn

phone no Phone Number: +13*********

Who is IMAGINAB

ImaginAb is a clinical stage, revenue-generating global biotechnology company developing the next generation of imaging agents and radiopharmaceutical therapy (RPT) products through its p...

Read More

map
  • 423 Hindry Ave Ste D, Inglewood, California, 90301, United States Headquarters: 423 Hindry Ave Ste D, Inglewood, California, 90301, United States
  • 2007 Date Founded: 2007
  • 11-50 Employees: 11-50
  • dollar-icon Revenue: $1 Million to $5 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 8731 | NAICS Code: 621511 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from IMAGINAB

ImaginAb Org Chart and Mapping

Employees

Alessandro Mascioni

Director of Research - Biologics Discovery

Calmen Tihansky

Sales Lead and Marketing Manager

Isabel Espinoza

Accounts Payable Specialist

William Le

Vice President, Global Operations | Senior Director of Clinical Development | Program Director

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding ImaginAb

Answer: ImaginAb's headquarters are located at 423 Hindry Ave Ste D, Inglewood, California, 90301, United States

Answer: ImaginAb's phone number is +13*********

Answer: ImaginAb's official website is https://imaginab.com

Answer: ImaginAb's revenue is $1 Million to $5 Million

Answer: ImaginAb's SIC: 8731

Answer: ImaginAb's NAICS: 621511

Answer: ImaginAb has 11-50 employees

Answer: ImaginAb is in Biotechnology

Answer: ImaginAb contact info: Phone number: +13********* Website: https://imaginab.com

Answer: ImaginAb is a clinical stage, revenue-generating global biotechnology company developing the next generation of imaging agents and radiopharmaceutical therapy (RPT) products through its proprietary minibody and cys-diabody platforms. The lead candidate 89Zr crefmirlimab berdoxam (CD8 ImmunoPETTM) imaging agent is currently in Phase II clinical trials and has been licensed by numerous pharmaceutical and biotech companies for use in imaging within their immunotherapy clinical trials, primarily in oncology.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access